

1 **Severity of maternal SARS-CoV-2 infection and perinatal outcomes during the**  
2 **Omicron variant dominant period: UK Obstetric Surveillance System national cohort**  
3 **study.**

4  
5 Keywords: COVID-19, vaccines, pregnancy, SARS-CoV-2 variant, Omicron, respiratory  
6 support.

7 Word count: main text excluding tables 3046

8  
9 Hilde Marie Engjom<sup>\*1,2</sup>, Rema Ramakrishnan<sup>\*1</sup>, Nicola Vousden<sup>1</sup>, Kathryn Bunch<sup>1</sup>, Edward  
10 Morris<sup>3</sup>, Nigel Simpson<sup>4</sup>, Chris Gale<sup>5</sup>, Pat O'Brien<sup>3,6</sup>, Maria Quigley<sup>1</sup>, Peter Brocklehurst<sup>7</sup>,  
11 Jennifer J Kurinczuk<sup>1</sup>, Marian Knight<sup>1</sup>

12  
13 <sup>\*</sup>Joint first authors

14  
15 <sup>1</sup>Nicola Vousden, Registrar in Public Health; Rema Ramakrishnan, CSOR/EXPRESS Senior  
16 Statistician; Kathryn Bunch, Epidemiologist; Maria Quigley, Professor of Statistical  
17 Epidemiology; Jennifer J Kurinczuk, Professor of Perinatal Epidemiology; Marian Knight,  
18 Professor of Maternal and Child Population Health: National Perinatal Epidemiology Unit,  
19 Nuffield Department of Population Health, University of Oxford, UK, OX3 7LF

20 <sup>2</sup>Hilde Marie Engjom, Consultant in Obstetrics and Gynecology, postdoctoral researcher,  
21 Division for Physical and Mental Health, Norwegian Institute of Public Health, 5015 Bergen,  
22 Norway

23 <sup>3</sup>Edward Morris, President of RCOG, Pat O'Brien, Vice President of RCOG: Royal College of  
24 Obstetricians and Gynaecologists, London, UK, SE1 1SZ

25 <sup>4</sup>Nigel Simpson, Senior Clinical Lecturer and Consultant in Obstetrics and Gynaecology:  
26 Department of Women's and Children's Health, School of Medicine, University of Leeds, UK,  
27 LS2 9JT

28 <sup>5</sup>Chris Gale, Reader in Neonatal Medicine and Honorary Consultant Neonatologist, Neonatal  
29 Medicine, School of Public Health, Faculty of Medicine, Imperial College London, London,  
30 UK, SW7 2BX

31 <sup>6</sup>Pat O'Brien, Consultant in Obstetrics and Gynaecology: Institute for Women's Health,  
32 University College London, London, UK

33 <sup>7</sup>Peter Brocklehurst. Professor of Women's Health, Birmingham Clinical Trials Unit, Institute  
34 of Applied Health Research, University of Birmingham, UK

35  
36 Corresponding author: Marian Knight  
37 National Perinatal Epidemiology Unit,

38 Nuffield Department of Population Health,  
39 University of Oxford,  
40 UK  
41 01865 289700  
42 [marian.knight@npeu.ox.ac.uk](mailto:marian.knight@npeu.ox.ac.uk)  
43  
44

45 **ABSTRACT**

46 **Objectives**

47 To describe the severity of maternal infection when the Omicron SARS-CoV-2 variant was  
48 dominant (15/12/21-14/01/22) and compare outcomes among groups with different  
49 vaccination status.

50 **Design:** Prospective cohort study

51 **Setting:** UK consultant-led maternity units

52 **Participants:** Pregnant women hospitalised with a positive SARS-CoV-2 PCR test up to 7  
53 days prior to admission and/or during admission up to 2 days after giving birth.

54 **Main outcome measures:** Symptomatic or asymptomatic infection. Vaccination status.  
55 Severity of maternal infection (moderate or severe infection according to modified WHO  
56 criteria). Mode of birth and perinatal outcomes.

57 **Results:** Out of 1561 women admitted to hospital with SARS-CoV-2 infection, 449 (28.8%)  
58 were symptomatic. Among symptomatic women admitted, 86 (19.2%) had moderate to  
59 severe infection; 51 (11.4%) had pneumonia on imaging, 62 (14.3%) received respiratory  
60 support, and 19 (4.2%) were admitted to the intensive care unit (ICU). Three women died  
61 (0.7%). Vaccination status was known for 383 symptomatic women (85.3%) women; 249  
62 (65.0%) were unvaccinated, 45 (11.7%) had received one vaccine dose, 76 (19.8%) had  
63 received two doses and 13 (3.4%) had received three doses. 59/249 (23.7%) unvaccinated  
64 women had moderate to severe infection, compared to 10/45 (22.2%) who had one dose,  
65 9/76 (11.8%) who had two doses and 0/13 (0%) who had three doses. Among the 19  
66 symptomatic women admitted to ICU, 14 (73.7%) were unvaccinated, 3 (15.8%) had  
67 received one dose, 1 (5.3%) had received two doses, 0 (0%) had received 3 doses and 1  
68 (5.3%) had unknown vaccination status.

69 **Conclusion**

70 The risk of severe respiratory disease amongst unvaccinated pregnant women admitted with  
71 symptomatic SARS-CoV-2 infection during the Omicron dominance period was comparable  
72 to that observed during the period the wildtype variant was dominant. Most women with  
73 severe disease were unvaccinated. Vaccine coverage among pregnant women admitted  
74 with SARS-CoV-2 was low compared to the overall pregnancy population and very low  
75 compared to the general population. Ongoing action to prioritise and advocate for vaccine  
76 uptake in pregnancy is essential.

## **SUMMARY BOX**

### **What is already known on this topic**

- In non-pregnant adults, growing evidence indicates a lower risk of severe respiratory disease with the Omicron SARS-CoV-2 Variant of Concern (VOC) .
- Pregnant women admitted during the periods in which the Alpha and Delta VOC were dominant were at increased risk of moderate to severe SARS-CoV-2 infection compared to the period when the original wildtype infection was dominant.
- Most women admitted to hospital with symptomatic SARS-CoV-2 infection have been unvaccinated.

### **What this study adds**

- One in four women who had received no vaccine or a single dose had moderate to severe infection, compared with one in eight women who had received two doses and no women who had received three doses
- The proportional rate of moderate to severe infection in unvaccinated pregnant women during the Omicron dominance period is similar to the rate observed during the wildtype dominance period
- One in eight symptomatic admitted pregnant women needed respiratory support during the period when Omicron was dominant

## 78 INTRODUCTION

79 In 2020 the World Health Organization's (WHO) living systematic review concluded that  
80 SARS-CoV-2 infection during pregnancy was associated with an increased risk of admission  
81 to intensive care (ICU) for the mother, increased risk of preterm birth and admission for  
82 neonatal care for the infant.<sup>1</sup> Included studies initially contained data predominately from the  
83 USA and China, with few active population-based surveillance studies. The last update was  
84 published in April 2021 and consequently included studies comprise mainly the Variants of  
85 Concern (VOC) prior to Delta.

86

87 In the UK, a new SARS-CoV-2 VOC (B.1.1.529, Omicron) was initially reported in November  
88 2021 and dominated by mid-December 2021.<sup>2</sup> With the Alpha (B.1.1.7) and Delta (B.1.617)  
89 VOC, severe maternal infection was more frequent compared to the wildtype period, and  
90 perinatal outcomes were worse<sup>3-5</sup>. The majority of severe maternal and perinatal outcomes  
91 occurred among unvaccinated women during periods with alpha and delta as dominant  
92 variants.<sup>6 7 8</sup> Initial studies of Omicron infection in non-pregnant populations indicate a lower  
93 risk of severe pulmonary disease with this variant compared to the previous delta VOC.<sup>9-11</sup>

94

95 To date we have not identified any peer-reviewed published studies exploring the impact of  
96 infection with the Omicron SARS-CoV-2 variant on pregnant women and perinatal outcomes.  
97 There is an urgent need for robust national data to inform women who are pregnant or plan a  
98 pregnancy, as well as health professionals providing care for pregnant women, and policy  
99 makers. The primary aim of this study was therefore to describe the characteristics of  
100 pregnant women admitted to hospital with SARS-CoV-2 infection including vaccination  
101 status, severity of infection, pharmacologic management, pregnancy, and perinatal  
102 outcomes, in the first period when the Omicron VOC was dominant in the UK.

103

## 104 METHODS

105

### 106 Design, data sources and study period

107 A national, prospective observational cohort study was conducted using the UK Obstetric  
108 Surveillance System (UKOSS).<sup>12</sup> This system entails active surveillance with reporting from  
109 all 194 hospitals in the UK with a consultant-led maternity unit, and includes well established  
110 routines to secure complete reporting.<sup>13</sup> Information on women who died, or who had  
111 stillbirths or neonatal deaths, was cross-checked with data from the organisation responsible  
112 for maternal and perinatal death surveillance in the UK (MBRRACE-UK).<sup>14</sup> As individual-  
113 level SARS-CoV-2 variant data were not recorded in medical records, the data collection  
114 time period was restricted to the period in which the Omicron SARS-CoV-2 variant was the

115 dominant circulating strain in the UK. The cut-off at December 15 was chosen since the  
116 variant then represented 50% or more of sequenced new cases from Public Health  
117 England.<sup>11</sup>

118

### 119 **Study population and study groups**

120 Women were included if they were admitted to hospital during pregnancy and had a positive  
121 SARS-CoV-2 PCR test at the time of admission. Hospital admission was defined as an  
122 overnight or longer hospital admission for any cause, or admission of any duration to give  
123 birth. Women not meeting this case definition were excluded (Figure 1). The included  
124 women were categorised in two mutually exclusive groups based on covid-19 symptoms.

125 Symptomatic group: women who were admitted due to covid-19 or who were reported to be  
126 symptomatic or who received respiratory support of any kind.

127 Asymptomatic group: women admitted for labour, obstetric care or other reasons and who  
128 were not reported to have SARS-CoV-2-related symptoms and who did not receive  
129 respiratory support, or who were reported to be asymptomatic if the reason for admission  
130 was not known.

131 Vaccination status was categorised as follows; unvaccinated, one dose, two doses and three  
132 doses, or vaccination status unknown.

133

### 134 **Measures**

135 A composite measure indicating moderate to severe SARS-CoV-2 infection was based on  
136 the WHO criteria of covid-19 disease severity.<sup>15</sup> Women were classified as having moderate  
137 to severe respiratory disease if one or more of the following was reported: oxygen saturation  
138 <95% on admission, need for respiratory support, evidence of pneumonia on imaging,  
139 admission to ICU, or maternal death. Respiratory support was recorded as the maximum  
140 level of support in one of the following categories: oxygen therapy (supplementation on nasal  
141 prongs or non-rebreathe mask <15 l/min), high-flow nasal cannula ≥15 l/min or continuous  
142 positive airway pressure (CPAP), mechanical ventilation (MV) or extracorporeal membrane  
143 oxygenation (ECMO). Mode of birth was categorised as follows; caesarean section prior to  
144 or in labour, assisted vaginal birth, unassisted vaginal birth. Gestational age was categorised  
145 by completed weeks as <22 weeks, 22 to 27 weeks, 28 to 33 weeks, 34 to 36 weeks and  
146 ≥37 weeks for gestational age at admission and gestational age at childbirth. The following  
147 perinatal outcomes were included: total births, live births, stillbirths, neonatal unit (NNU)  
148 admission, early neonatal death.

149 The following sociodemographic and medical risk factors were included: maternal age, body  
150 mass index (BMI) in kg/m<sup>2</sup>, occupation (woman or partner in paid work vs neither in paid  
151 work), minority ethnic background (Asian, Black, Chinese, other or mixed ethnic minorities vs

152 White), smoking (current smoker vs non-smoker), medical conditions prior to or during  
153 pregnancy (asthma, hypertension, cardiac disease, and diabetes prior to or in pregnancy),  
154 parity (nulliparous vs multiparous), plurality (singleton vs multiple).

155

156 Descriptions of pharmacological therapies were based on national guidance on  
157 pharmacological therapy issued on 01/07/2020 using the current edition at the time of  
158 admission<sup>16</sup>.

159

### 160 **Study registration**

161 The study was registered with ISRCTN, number 40092247 and the protocol is available at  
162 <https://www.npeu.ox.ac.uk/ukoss/current-surveillance/covid-19-in-pregnancy>.

163

### 164 **Role of the funding source**

165 The funder played no role in study design; in the collection, analysis, and interpretation of  
166 data; in the writing of the report; or in the decision to submit the paper for publication.

167

### 168 **Ethics and consent**

169 This study was approved by the HRA NRES Committee East Midlands – Nottingham 1  
170 (Ref. Number: 12/EM/0365).

171

### 172 **Patient and Public Involvement**

173 Patients and public were part of the UKOSS steering committee and involved in study  
174 oversight but not in the design, reporting, conduct or dissemination of this study.

175

### 176 **Statistical methods and analysis**

177 Continuous variables were summarised by medians with interquartile range (IQR) for non-  
178 normal distributions. Numbers and proportions are presented, and where data were missing,  
179 proportions are presented out of cases known. Statistical analyses were performed using  
180 STATA version 17 (Statacorp, TX, USA).

181

182 In this national observational study, the study sample size was governed by the disease  
183 incidence, thus no formal power calculation was carried out.

184

185

186

187

188

## 189 **RESULTS**

190 Of the 1561 women admitted with confirmed SARS-CoV-2 infection between 15<sup>th</sup> December  
191 2021 and 14<sup>th</sup> January 2022 (Figure 1), 449 (28.8%) were symptomatic and 1112 (71.2%)  
192 were asymptomatic.

193

194 The characteristics of included women stratified by admission group are shown in Table 1.  
195 The proportion of women aged 35 years or over was similar among symptomatic and  
196 asymptomatic women: 27.5% (n=115) and 26.3% (n=278), respectively. BMI of 30kg/m<sup>2</sup> or  
197 more was reported for 29.7% (n=127) and 27.1% (n=289) among symptomatic and  
198 asymptomatic women, respectively. Black, Asian or other minority background was reported  
199 for 33.5% (n=147) and 38.4% (n=412). In the symptomatic group, 50.8% (n=224) had a  
200 gestational age at admission from 22 to 36 completed weeks; this proportion was 22.8%  
201 (n=227) in the asymptomatic group. Vaccination status was known for 1274 women (81.6%),  
202 383 in the symptomatic group and 891 in the asymptomatic group.

203

### 204 **Respiratory support and medical treatment for symptomatic women**

205 Two women (0.2%) in the asymptomatic group were admitted to ICU for indications  
206 unrelated to their SARS-CoV-2 infection. Overall, 86 (19.2%) of the symptomatic women had  
207 at least one indicator of moderate to severe infection (Table 2). However, the proportion of  
208 symptomatic women who received any specific pharmacological therapy was low (n=31,  
209 6.9%); 0.4% (n=2) received antivirals, 1.6% (n=7) received tocilizumab, 5.8% (n=26)  
210 received corticosteroids for maternal indication, and 0.9% (n=4) received monoclonal  
211 antibodies. Four women were recruited to the RECOVERY trial. Among the 19 symptomatic  
212 women admitted to ICU, 10 (52.6%) received a specific pharmacological therapy, 1 woman  
213 (5.3%) received antivirals, 4 (21.0%) received tocilizumab, 9 (47.4%) received  
214 corticosteroids for a maternal indication and 2 (10.5%) received monoclonal antibodies.

215

### 216 **Vaccination status**

217 The proportion of symptomatic women who had received none, one, two or three vaccine  
218 doses was 65.1% (n=249), 11.8% (n=45), 19.8% (n=76), and 3.4% (n=13), respectively  
219 (Table 1). A total of 78 (20.4%) symptomatic women whose vaccination status was known  
220 had a composite measure of moderate to severe infection. More than a fifth of unvaccinated  
221 women (59/249, 23.7%) and women who had received one dose (10/45, 22.2%) had  
222 moderate to severe infection, compared to one in ten (9/76, 11.8%) who had two doses and  
223 none (0/13, 0%) who had three doses. Forty of the women in the two-dose group (52.6%)  
224 were known to have received their second vaccine dose more than three months prior to



225 admission; this included five of the nine women who had a composite indicator of moderate  
226 to severe infection and the woman who was admitted to ICU. Overall, none of the women  
227 (0/68) who had a composite indicator of moderate to severe infection and known vaccination  
228 status had completed the vaccination schedule advised to protect the general adult  
229 population against severe omicron infection.

230

### 231 **Pregnancy outcomes**

232 One thousand, one hundred and seventy-two women had completed their pregnancies, 240  
233 (53.5%) of the women in the symptomatic group and 932 (83.8%) in the asymptomatic group  
234 (Table 4). Almost a third of symptomatic women (n=144, 32.1%) were known to have been  
235 discharged still pregnant. The proportion of births at gestational weeks 22 to 36 was 17.8%  
236 (n=42) amongst symptomatic women versus 10.7% (n=96) in asymptomatic women. Birth  
237 expedited due to covid-19 was reported for 7.6% (n=18) in the symptomatic group; none of  
238 these women were known to have received three vaccine doses (Table 5).

239

240 Among 1159 infants, 10 stillbirths were reported; in the symptomatic and asymptomatic  
241 groups stillbirths occurred in 0.8% (n=2) and 0.9% (n=8) of total births, respectively (Table  
242 6). Eight of the ten stillbirths occurred to women who were unvaccinated or had one vaccine  
243 dose, but the role of SARS-CoV-2 in the stillbirth needs to be assessed in formal audit.  
244 Admission to a neonatal unit was reported for 15.4% (n=37) of infants born to symptomatic  
245 women and 8.5% (n=78) of infants born to asymptomatic women.

246

## 247 **DISCUSSION**

### 248 ***Principal findings***

249 This national prospective cohort study has identified that among pregnant women admitted  
250 with SARS-CoV-2 infection during the period when the Omicron VOC was dominant around  
251 one in four were symptomatic. One in seven of these symptomatic pregnant women needed  
252 respiratory support. One in four symptomatic pregnant women who had received no vaccine  
253 or a single dose had moderate to severe infection. One in eight symptomatic pregnant  
254 women who had received two doses had moderate to severe infection. No symptomatic  
255 pregnant women who had received three doses had moderate or severe infection, though  
256 the number of pregnant women admitted with symptomatic SARS-CoV-2 infection who had  
257 received three vaccine doses was very small. No women with moderate to severe  
258 respiratory disease, ICU admission or who died had received vaccines according to the  
259 recommended schedule for the general adult population for the Omicron variant.

260

261

262

263 ***Strengths and weaknesses of the study***

264 To our knowledge, this is the first national prospective cohort study to describe pregnancy  
265 and perinatal outcomes during the period when the Omicron SARS-CoV-2 variant was  
266 dominant. A key strength of these data is the existing mechanism for national case  
267 identification of all women admitted to hospital across the UK, and therefore the low risk of  
268 selection bias. In the UK, universal SARS-CoV-2 testing for all obstetric admissions was  
269 implemented from May 2020. Asymptomatic pregnant women in whom SARS-CoV-2  
270 infection is detected by screening on admission, are most commonly admitted to give birth.<sup>17</sup>  
271 We therefore categorised the included women by cause of admission or symptoms to avoid  
272 misclassification bias and increased adverse outcomes being incorrectly attributed to SARS-  
273 CoV-2.<sup>18</sup>

274

275 Some of the pregnant women who had received two vaccine doses or fewer may also have  
276 delayed the second dose due to covid-19 infection; information about previous infection was  
277 not available in the current study. These women could potentially be misclassified into a  
278 category with lower expected protection while having reduced risk due to post-infection  
279 immunity, and this could result in overestimation of the protective effect of different vaccine  
280 doses. As with previous analyses,<sup>5</sup> variant sequencing data were not available for individual  
281 women, and a proxy time period was used instead which may be considered a limitation.  
282 Additionally, more women in the symptomatic group have not completed their pregnancies,  
283 compared to the asymptomatic group, which is likely to affect the observed rates of key  
284 neonatal outcomes.

285

286 ***Interpretation and comparison with related studies***

287 The proportion of symptomatic women with moderate to severe infection was lower overall  
288 than in the wildtype, Alpha and Delta variant periods in the UK<sup>5 13</sup>. However, a greater  
289 proportion of symptomatic pregnant women had received one or more vaccine doses than in  
290 previous variant periods and this needs to be taken into account when comparing outcomes  
291 across variant periods, recognising that prior vaccination is likely to confer some degree of  
292 protection from both severe illness and symptomatic infection. When solely unvaccinated  
293 pregnant women admitted with symptomatic infection are considered, maternal outcomes  
294 are very similar to those observed during the initial wildtype infection period<sup>5</sup>. Among those  
295 in need of respiratory support, irrespective of vaccination status, the use of mechanic  
296 ventilation or ECMO was 16.1% (10/62) and thus lower than previous periods (23.5% in  
297 Alpha and 21.4% in Delta periods)<sup>5</sup>.

298

299 Covid-19-specific pharmacological therapies, which are now standard care for non-pregnant  
300 patients, were used infrequently, even for women that needed respiratory support. The  
301 proportion that received any pharmacological treatment for covid-19 (one or more of an  
302 antiviral, tocilizumab, maternal corticosteroids and monoclonal antibodies) was lower than in  
303 the Alpha and Delta periods, 6.9% vs 14.9% and 13.6% respectively. While this may partly  
304 reflect a lower severity of illness, it is concerning that only around half of pregnant women  
305 admitted to ICU due to covid-19 received any covid-19 specific pharmacological treatment.  
306 The RCOG recommended in June 2020 that corticosteroid therapy should be considered for  
307 all women who were clinically deteriorating due to covid-19.<sup>16</sup> Maternal corticosteroid  
308 treatment was reported for 5.8% of symptomatic women during the Omicron period,  
309 compared to 12.7% and 12.0% during the Alpha and Delta periods, respectively. In the  
310 current study 47% of women admitted to intensive care received corticosteroids.  
311 Understanding this persisting low use of evidence-based therapies amongst severely ill  
312 pregnant and postpartum women is an increasingly urgent priority.

313

314 Few pregnant women who had received two or more doses of vaccine were admitted with  
315 symptomatic SARS-CoV-2, and none of the women with a composite indicator for moderate  
316 or severe infection had received three vaccine doses according to current recommendations  
317 to protect non-pregnant adults against severe omicron infection. Vaccination for all pregnant  
318 women regardless of risk group in the UK was recommended from 16<sup>th</sup> April 2021, and all  
319 adults were eligible to receive vaccination from mid-June 2021.<sup>19</sup> Vaccine coverage  
320 surveillance among women who gave birth in England up to October 2021 reported that  
321 29.4% of the women had received two doses of vaccine and 58.2% were unvaccinated<sup>20</sup>.  
322 Similarly, vaccine coverage has been low in Scotland where 32.2% of women who gave birth  
323 in October 2021 had received two doses of vaccine during pregnancy compared to 77.4% of  
324 women of reproductive age (18-44 years), and 98.1% of women admitted to the ICU were  
325 unvaccinated.<sup>6</sup> Almost 68% of the women with information about vaccination status included  
326 in the current study were unvaccinated.

327

328 In the general adult population, effectiveness after the second dose declines from 60-75%  
329 three weeks after vaccination to 20% at 15 weeks and 10% after 25 weeks,<sup>20</sup> and three  
330 doses have been shown to give better protection against severe disease with the Omicron  
331 VOC in adults.<sup>21</sup> The interval between the last dose and the admission was 3 months or  
332 more among half (53%) of the women who had received two doses of vaccine. The number  
333 of pregnant women who had received a third booster dose was low in our study, but no  
334 severe cases in this group indicates the importance of the third dose to protect pregnant

335 women from both hospital admission with symptomatic covid-19 and need for respiratory  
336 support.

337

338 Disproportionate admissions due to covid-19 among pregnant women with ethnic minority  
339 backgrounds were less prominent in the current study than previously described during the  
340 wildtype period.<sup>13</sup> National guidance has emphasised the importance of addressing this  
341 inequality and advised active health seeking in these groups.<sup>16</sup> The observation time in the  
342 current study is short and the findings cannot yet reliably indicate if the smaller differences  
343 can be attributed to better communication, prevention, health care seeking strategies or  
344 previous infection. Preliminary surveillance results indicated that the Omicron VOC has a  
345 secondary attack rate of 10-13% and therefore factors that increase transmission, such as  
346 multi-occupancy housing and public-facing occupations, are important also for this variant.<sup>22-</sup>  
347 <sup>24</sup> Since socioeconomic deprivation is also a known independent risk factor for adverse  
348 pregnancy outcome, this could be a source of residual confounding in this study.

349

350 Neonatal outcomes were purposely not compared between omicron and other periods as a  
351 high proportion of pregnancies were continuing at the time of analysis. However, the  
352 available data suggest that the risk of stillbirth during this period may be lower than observed  
353 during the delta period<sup>5</sup>. Further follow-up is required to clarify the effect of infection during  
354 the Omicron dominant period on perinatal outcomes such as stillbirth.

355

### 356 ***Implications for clinicians and policymakers***

357 The findings of this study indicate that the risk of severe respiratory failure in unvaccinated  
358 pregnant women with Omicron VOC is similar to that observed in the UK during the initial  
359 wildtype variant wave of the pandemic.<sup>13</sup> While severe outcomes were less frequent in the  
360 current period compared to the previous Alpha and Delta variant dominant periods, it is  
361 important to keep in mind that the risk of hospital admission due to covid-19 was higher in  
362 the UK than in other European countries during the initial months of the pandemic,<sup>25 26</sup>  
363 possibly associated with early implementation of public health measures to limit viral  
364 transmission. If public health interventions could to some extent protect pregnant women  
365 during the first wave, individual protection through vaccination is now available. Our results  
366 indicate that most current cases of respiratory failure among pregnant women are  
367 preventable, yet vaccine uptake among pregnant women remains low compared to the  
368 general female population in fertile age. Continued, strong efforts to improve uptake of the  
369 vaccine during pregnancy are still needed. This is of even greater importance as infection  
370 continues to rapidly rise in both high and low-resourced settings.<sup>27</sup>

371



373 **Data Sharing**

374 Data cannot be shared publicly because of confidentiality issues and potential identifiability  
375 of sensitive data as identified within the Research Ethics Committee application/approval.  
376 Requests to access the data can be made by contacting the National Perinatal Epidemiology  
377 Unit data access committee via [general@npeu.ox.ac.uk](mailto:general@npeu.ox.ac.uk).

378

379 **Competing Interest**

380 All authors have completed the ICMJE uniform disclosure form  
381 [www.icmje.org/coi\\_disclosure.pdf](http://www.icmje.org/coi_disclosure.pdf) and declare: MK, MQ, PB, PO'B, JJK received grants from  
382 the NIHR in relation to the submitted work. HE participated in this work as academic visitor  
383 to the NPEU with funding from The Norwegian Research Council, grant no 320181, and  
384 travel grant from the Nordic Federation Of Societies of Obstetrics and Gynecology Research  
385 fund, grant no 6302. KB, NV, RR, NS, CG have no conflicts of interest to declare. EM is  
386 Trustee and President of RCOG, Trustee of British Menopause Society and Chair of the  
387 Board of Trustees Group B Strep Support. PO'B is Vice President of RCOG and Co-Chair of  
388 the RCOG Vaccine Committee. No other relationships or activities that could appear to have  
389 influenced the submitted work.

390

391 **Acknowledgements**

392 The authors would like to acknowledge the assistance of UKOSS reporting clinicians, the  
393 NIHR Reproductive Health & Childbirth National Research Champions, and the UKOSS  
394 Steering Committee without whose support this research would not have been possible.

395

396 **Contributorship statement**

397 All authors contributed to conceptualisation, the writing and editing of this study, had final  
398 approval of the version to be published and agree to be accountable for all aspects of the  
399 work. KB, EM, NS, CG, PO, MQ, PB, JK and MK contributed to funding acquisition,  
400 supervision, and methodology. HE, RR, NV, KB and MK contributed to data curation and  
401 formal analysis, and had access to verify the underlying data. MK, as guarantor, accepts full  
402 responsibility for the work and affirms that the manuscript is an honest, accurate and  
403 transparent account of the study being reported; that no important aspects of the study have  
404 been omitted; and that any discrepancies from the study as originally planned have been  
405 explained. The corresponding author attests that all listed authors meet authorship criteria  
406 and that no others meeting the criteria have been omitted.

407 The Corresponding Author has the right to grant on behalf of all authors and does grant on  
408 behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in  
409 all forms, formats and media (whether known now or created in the future), to i) publish,  
410 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into  
411 other languages, create adaptations, reprints, include within collections and create  
412 summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative  
413 work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v)  
414 the inclusion of electronic links from the Contribution to third party material where-ever it may  
415 be located; and, vi) licence any third party to do any or all of the above.

416

#### 417 **Funding**

418 The study was funded by the National Institute for Health Research HS&DR Programme  
419 (project number 11/46/12). MK is an NIHR Senior Investigator. The views expressed are  
420 those of the authors and not necessarily those of the NHS, the NIHR or the Department of  
421 Health and Social Care.

422

423


424

## 425 REFERENCES

- 426 1. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal  
427 and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic  
428 review and meta-analysis. *BMJ* 2020;370:m3320-m20. doi: 10.1136/bmj.m3320
- 429 2. World Health Organization. Tracking SARS-CoV-2 variants Geneva: World Health  
430 Organization,; 2021 [cited 2021 13th July ]. Available from:  
431 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> accessed 13th July  
432 2021
- 433 3. Donati S, Corsi E, Maraschini A, et al. SARS-CoV-2 infection among hospitalised  
434 pregnant women and impact of different viral strains on COVID-19 severity in Italy: a  
435 national prospective population-based cohort study. *BJOG* 2022;129(2):221-31. doi:  
436 10.1111/1471-0528.16980 [published Online First: 2021/10/24]
- 437 4. DeSisto CL, Wallace B, Simeone RM, et al. Risk for Stillbirth Among Women With and  
438 Without COVID-19 at Delivery Hospitalization - United States, March 2020-  
439 September 2021. *Mmwr-Morbid Mortal W* 2021;70(47):1640-45.
- 440 5. Vousden N, Bunch K, Morris E, et al. Severity of maternal infection and perinatal  
441 outcomes during periods in which Wildtype, Alpha and Delta SARS-CoV-2 variants  
442 were dominant: Data from the UK Obstetric Surveillance System national cohort.  
443 *BMJ Medicine* 2022;In Press
- 444 6. Stock SJ, Carruthers J, Calvert C, et al. SARS-CoV-2 infection and COVID-19 vaccination  
445 rates in pregnant women in Scotland. *Nat Med* 2022 doi: 10.1038/s41591-021-  
446 01666-2 [published Online First: 2022/01/15]
- 447 7. Engjom H, van den Akker T, Aabakke A, et al. Severe COVID-19 in pregnancy is almost  
448 exclusively limited to unvaccinated women - time for policies to change. *Lancet Reg  
449 Health Eur* 2022;13:100313. doi: 10.1016/j.lanpe.2022.100313 [published Online  
450 First: 2022/02/01]
- 451 8. Vousden N, Bunch K, Morris E, et al. Management and implications of severe COVID-19  
452 in pregnancy in the UK: Data from the UK Obstetric Surveillance System national  
453 cohort. *Acta Obstet Gynecol Scand* 2022
- 454 9. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under  
455 investigation in England. Technical briefing: update on hospitalisation and vaccine  
456 effectiveness for omicron VOC (B.1.1.529). 2021.
- 457 10. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the  
458 SARS-CoV-2 omicron variant in South Africa: a data linkage study. *Lancet*  
459 2022;399(10323):437-46. doi: 10.1016/S0140-6736(22)00017-4 [published Online  
460 First: 2022/01/23]
- 461 11. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under  
462 investigation in England Technical briefing 33, 2021.
- 463 12. Knight M, Kurinczuk JJ, Tuffnell D, et al. The UK Obstetric Surveillance System for rare  
464 disorders of pregnancy. *BJOG* 2005;112(3):263-5. doi: 10.1111/j.1471-  
465 0528.2005.00609.x
- 466 13. Knight M, Bunch K, Vousden N, et al. Characteristics and outcomes of pregnant women  
467 admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population  
468 based cohort study. *BMJ* 2020;369:m2107. doi: 10.1136/bmj.m2107
- 469 14. Knight M BK, Tuffnell D, Jayakody H, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ  
470 (Eds.) on behalf of MBRRACE-UK,. Saving Lives, Improving Mothers' Care -  
471 Lessons learned to inform maternity care from the UK and Ireland Confidential  
472 Enquiries into Maternal Deaths and Morbidity 2014-16. . In: Oxford: National  
473 Perinatal Epidemiology Unit, ed. University of Oxford, 2018.
- 474 15. World Health Organisation. COVID-19 Clinical Management: Living guidance 25 January  
475 2021 Geneva: World Health Organisation, , 2021.
- 476 16. Royal College of Obstetricians and Gynaecologists and Royal College of Midwives.  
477 Coronavirus (COVID-19) infection in pregnancy, information for healthcare  
478 professionals. London,; Royal College of Obstetricians and Gynaecologists, 2021.



- 479 17. Vousden N, Bunch K, Morris E, et al. The incidence, characteristics and outcomes of  
480 pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2  
481 infection in the UK from March to September 2020: A national cohort study using the  
482 UK Obstetric Surveillance System (UKOSS). *PLoS One* 2021;16(5):e0251123. doi:  
483 10.1371/journal.pone.0251123 [published Online First: 2021/05/06]
- 484 18. Knight M, Draper E, Kurinczuk JJ. Misclassification bias and unnecessary anxiety.  
485 *American Journal of Obstetrics and Gynecology* 2021;225(5):584. doi:  
486 <https://doi.org/10.1016/j.ajog.2021.06.086>
- 487 19. Public Health England. Health chiefs encourage more pregnant women to get their  
488 COVID-19 vaccine London: Public Health England, 2021.
- 489 20. UK Health Security Agency. COVID-19 vaccine surveillance report report Week 4 27  
490 January 2022, 2022.
- 491 21. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA  
492 COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron  
493 and Delta Variants. *JAMA* 2022 doi: 10.1001/jama.2022.0470 [published Online First:  
494 2022/01/22]
- 495 22. Cevik M, Mishra S. SARS-CoV-2 variants and considerations of inferring causality on  
496 disease severity. *The Lancet Infectious Diseases* 2021;21(11):1472-74. doi:  
497 10.1016/S1473-3099(21)00338-8
- 498 23. Piekos SN, Roper RT, Hwang YM, et al. The effect of maternal SARS-CoV-2 infection  
499 timing on birth outcomes: a retrospective multicentre cohort study. *Lancet Digit  
500 Health* 2022;4(2):e95-e104. doi: 10.1016/S2589-7500(21)00250-8 [published Online  
501 First: 2022/01/18]
- 502 24. UK Health Security Agency. SARS-CoV-2 variants of concern and variants under  
503 investigation in England Technical briefing 35, 2022.
- 504 25. Engjom H, Aabakke AJ, Klungsoyr K, et al. COVID-19 in pregnancy - characteristics and  
505 outcomes of pregnant women admitted to hospital because of SARS-CoV-2 infection  
506 in the Nordic countries. *Acta Obstet Gynecol Scand* 2021 doi: 10.1111/aogs.14160  
507 [published Online First: 2021/04/23]
- 508 26. Donati S, Corsi E, Maraschini A, et al. The first SARS-CoV-2 wave among pregnant  
509 women in Italy: results from a prospective population-based study. *Ann Ist Super  
510 Sanita* 2021;57(4):272-85. doi: 10.4415/ANN\_21\_04\_02 [published Online First:  
511 2022/01/26]
- 512 27. Burn-Mudoch JPD. Delta variant takes hold in developing world as infections soar.  
513 *Financial Times* 2021.  
514  
515  
516  
517



518

519 **Figure 1 Inclusion flow chart:** pregnant women admitted to hospital with SARS-CoV-2

520 infection, by admission group, UK, 15<sup>th</sup> December 2021 to 14<sup>th</sup> January 2022

521

522 **Table 1** Sociodemographic characteristics and medical risk factors among pregnant women  
 523 admitted with SARS-CoV-2, by admission group, UK, 15<sup>th</sup> December 2021 to 14<sup>th</sup> January  
 524 2022

Characteristic	Symptomatic (n,%) (n=449)	Asymptomatic (n,%) (n=1112)
Age (years):		
<20	9 (2.2)	31 (2.9)
20-34	294 (70.3)	750 (70.8)
≥35	115 (27.5)	278 (26.3)
Missing	31	53
Body Mass Index (BMI) (kg/m <sup>2</sup> ):		
Underweight (<18.5)	10 (2.3)	38 (3.6)
Normal (18.5 to <25)	161 (37.6)	417 (39.0)
Overweight (25 to <30)	130 (30.4)	324 (30.3)
Obese (>30)	127 (29.7)	289 (27.1)
Missing	21	44
Either woman or partner in paid work	341 (76.0)	841 (75.6)
Ethnic Group		
White	292 (66.5)	661 (61.6)
Asian	58 (13.2)	179 (16.7)
Black	53 (12.1)	162 (15.1)
Chinese/Other	12 (2.7)	40 (3.7)
Mixed	24 (5.5)	31 (2.9)
Missing	10	39
Current smoking	73 (16.9)	190 (17.7)
Missing	17	40
Pre-existing medical conditions		
Asthma	40 (8.9)	60 (5.4)
Hypertension	10 (2.2)	13 (1.2)
Cardiac disease	4 (0.9)	8 (0.7)
Diabetes	9 (2.0)	10 (0.9)
Multiparous	271 (61.0)	662 (60.9)
Missing	5	25
Multiple pregnancy	5 (1.1)	12 (1.1)
Gestation at admission (weeks)		
<22	32 (7.3)	67 (6.1)
22-27 <sup>+6</sup>	40 (9.1)	33 (3.0)
28-33 <sup>+6</sup>	100 (22.7)	81 (7.4)
34-36 <sup>+6</sup>	84 (19.1)	113 (10.3)
37 or more	185 (42.0)	800 (73.1)
Missing	8	18
Vaccination status		
Unvaccinated	249 (65.1)	625 (70.2)
1 dose	45 (11.8)	83 (9.3)
2 doses	76 (19.8)	154 (17.3)
3 doses	13 (3.4)	29 (3.2)
Not known/ not documented	66	221

525 **Table 2** Respiratory support and medical treatment to symptomatic pregnant women  
 526 admitted to hospital with SARS-CoV-2 infection, UK, 15<sup>th</sup> December 2021 to 14<sup>th</sup> January  
 527 2022

	Number of women n (%)
Total number	449
Composite indicator of moderate to severe infection	86 (19.2)
Oxygen saturation measured on admission (Yes)	392 (87.3)
Oxygen saturation <95%	18 (5.4)
Evidence of pneumonia on imaging	51 (11.4)
Respiratory support required	62 (14.3)
Non-invasive oxygen (nasal canulae, mask or non-rebreathe mask at <15l/min)	40 (69.0)
High flow nasal oxygen (≥15l/min) or CPAP*	8 (13.8)
Mechanic ventilation or ECMO <sup>†</sup>	10 (17.2)
Level not known	5
Intensive Care Unit admission	19 (4.2)
Maternal Death	3 (0.7)
Pharmacological Management Total <sup>‡</sup>	31 (6.9)
antivirals	2 (0.4)
tocilizumab	7 (1.6)
corticosteroids for maternal indication	26 (5.8)
monoclonal antibodies	4 (0.9)
recruited to RECOVERY-trial	4 (0.9)
* CPAP: continuous positive airway pressure	
† ECMO: extracorporeal membrane oxygenation.	
‡ Any of the listed medications given for medical management of SARS-CoV-2: antivirals, tocilizumab, maternal corticosteroids, monoclonal antibodies.	

528

529 **Table 3** Outcomes among symptomatic pregnant women admitted to hospital with SARS-  
 530 CoV-2 infection during the period when Omicron was the dominant variant by vaccination  
 531 status, UK, 15<sup>th</sup> December 2021 to 14<sup>th</sup> January 2022

	Unvaccinated n (%)	1 dose n (%)	2 doses n (%)	3 doses n (%)	Status unknown n (%)
Total number	249	45	(n=76)	(n=13)	(n=66)
Composite indicator of moderate to severe infection	59 (23.7)	10 (22.2)	9 (11.8)	0 (0.0)	8 (12.1)
Intensive Care admission	14 (5.6)	3 (6.7)	1 (1.3)	0 (0.0)	1 (1.5)
Maternal Death	2 (0.8)	1 (2.2)	0 (0.0)	0 (0.0)	0 (0.0)

532 **Table 4** Pregnancy outcomes for women admitted with SARS-CoV-2 infection during the  
 533 period when Omicron was the dominant variant, by cause of admission, UK, 15<sup>th</sup> December  
 534 2021 to 14<sup>th</sup> January 2022  
 535

<b>Pregnancy outcome</b>	<b>Symptomatic n (%)</b>	<b>Asymptomatic n (%)</b>
Total number	449	1112
Still pregnant, known to have been discharged	144 (32.1)	107 (9.6)
Still pregnant, not known to have been discharged	65 (14.5)	73 (6.6)
Pregnancy completed	240 (53.5)	932 (83.8)
Pregnancy Loss	3 (0.7)	27 (2.4)
Birth	237 (52.8)	905 (81.4)
Gestation at birth (weeks <sup>+days</sup> )*		
22 <sup>+0</sup> – 27 <sup>+6</sup>	1 (0.4)	6 (0.7)
28 <sup>+0</sup> – 33 <sup>+6</sup>	8 (3.4)	22 (2.5)
34 <sup>+0</sup> – 36 <sup>+6</sup>	33 (14.0)	68 (7.6)
37 <sup>+0</sup> or more	194 (82.2)	802 (89.3)
Missing	1	7
Birth expedited due to COVID-19*	18 (7.6)	0 (0.0)
Mode of birth*		
Pre-labour Caesarean	76 (32.1)	213 (23.7)
Caesarean after labour onset	45 (19.0)	127 (14.1)
Operative vaginal	24 (10.1)	104 (11.6)
Unassisted vaginal	92 (38.8)	454 (50.6)
Missing	0	7

\* Excluding pregnancy loss from denominator

**Table 5** Pregnancy outcomes for women admitted with SARS-CoV-2 infection during the period when Omicron was the dominant variant, by cause of admission and vaccination status, UK, 15<sup>th</sup> December 2021 to 14<sup>th</sup> January 2022.

Vaccination status	Symptomatic (n=449)					Asymptomatic (n=1,112)				
	Unvaccinated n (%)	1 dose only n (%)	2 doses n (%)	3 doses n (%)	Status unknown n (%)	Unvaccinated n (%)	1 dose n (%)	2 doses n (%)	3 doses n (%)	Status unknown n (%)
Total number	249	45	76	13	66	625	83	154	29	221
Still pregnant, known to have been discharged	71 (28.5)	16 (35.6)	23 (30.3)	6 (46.1)	28 (42.4)	47 (7.5)	9 (10.8)	15 (9.7)	4 (13.8)	32 (14.5)
Still pregnant, not known to have been discharged	38 (15.3)	3 (6.7)	15 (19.7)	0 (0.0)	9 (13.6)	50 (8.0)	4 (4.8)	8 (5.2)	1 (3.4)	10 (4.5)
Pregnancy completed	140 (56.2)	26 (57.8)	38 (50.0)	7 (53.9)	29 (43.9)	528 (84.5)	70 (84.3)	131 (85.1)	24 (82.8)	179 (81.0)
Pregnancy Loss	2 (0.8)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	13 (2.1)	2 (2.4)	4 (2.6)	2 (6.9)	6 (2.7)
Birth	138 (55.4)	26 (57.8)	37 (48.7)	7 (53.9)	29 (43.9)	515 (82.4)	68 (81.9)	127 (82.5)	22 (75.9)	173 (78.3)
Gestation at birth (weeks <sup>+days</sup> )*										
22 <sup>+0</sup> – 27 <sup>+6</sup>	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.2)
28 <sup>+0</sup> – 33 <sup>+6</sup>	5 (3.6)	1 (4.0)	0 (0.0)	0 (0.0)	2 (6.9)	7 (1.4)	5 (7.3)	7 (5.6)	0 (0.0)	3 (1.7)
34 <sup>+0</sup> – 36 <sup>+6</sup>	24 (17.4)	0 (0.0)	7 (18.9)	0 (0.0)	2 (6.9)	41 (8.0)	2 (2.9)	8 (6.4)	3 (13.6)	14 (8.2)
37 <sup>+0</sup> or more	108 (78.3)	24 (96.0)	30 (81.1)	7 (100.0)	25 (86.2)	460 (89.7)	61 (89.7)	110 (88.0)	19 (86.4)	152 (88.9)
Missing	0	1	0	0	0	3	0	2	0	2
Birth expedited due to COVID-19*	12 (8.7)	1 (3.8)	2 (5.4)	0 (0.0)	3 (10.3)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Mode of birth*										
Pre-labour Caesarean	42 (30.4)	12 (46.2)	12 (32.4)	1 (14.3)	9 (31.0)	110 (21.4)	23 (34.9)	34 (27.2)	7 (31.8)	39 (22.7)
Caesarean after labour onset	28 (20.3)	7 (26.9)	4 (10.8)	2 (28.6)	4 (13.8)	80 (15.6)	7 (10.6)	18 (14.4)	0 (0.0)	22 (12.8)
Operative vaginal	11 (8.0)	2 (7.7)	6 (16.2)	2 (28.6)	3 (10.3)	65 (12.7)	2 (3.0)	12 (9.6)	3 (13.6)	22 (12.8)
Unassisted vaginal	57 (41.3)	5 (19.2)	15 (40.5)	2 (28.6)	13 (44.8)	258 (50.3)	34 (51.5)	61 (48.8)	12 (54.6)	89 (51.7)
Missing	0	0	0	0	0	2	2	2	0	1

\*Excluding pregnancy loss from denominator

1 **Table 6:** Perinatal outcomes for women admitted with SARS-CoV-2 infection during the period when omicron was the dominant variant and  
 2 who have given birth (n=1159) by cause of admission and vaccination status, UK, 15<sup>th</sup> December 2021 to 14<sup>th</sup> January 2022.  
 3

Vaccine status	Symptomatic (n=242)					Asymptomatic (n=917)				
	Unvaccinated n (%)	1 dose n (%)	2 doses n (%)	3 doses n (%)	Status unknown n (%)	Unvaccinated n (%)	1 dose n (%)	2 doses n (%)	3 doses n (%)	Status unknown n (%)
Total number	141	27	37	7	30	521	68	130	23	175
Stillbirth	1 (0.7)	1 (3.7)	0 (0.0)	0 (0.0)	0 (0.0)	5 (1.0)	1 (1.5)	2 (1.5)	0 (0.0)	0 (0.0)
Admission to Neonatal Unit*	14 (10.0)	5 (19.2)	8 (21.6)	1 (14.3)	9 (30.0)	39 (7.6)	5 (7.5)	12 (9.5)	3 (13.0)	18 (10.3)
Neonatal Death	0 (0.0)	0 (0.0)	0 (0.0)	0(0.0)	0(0.0)	3 (0.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
*One infant (asymptomatic mother) had missing data for admission to neonatal unit.										

4